The Smoking Problem Did Not Disappear. It Evolved. And That Evolution Is Creating a New Opportunity.
Share
For decades, the global fight against smoking has been measured by one primary metric: the decline of traditional cigarette use. On the surface, that trend has shown progress in many developed markets. Public health campaigns have been effective, regulations have tightened, and awareness of smoking related risks is now widespread. However, focusing only on cigarette decline misses the more important shift that is taking place beneath the surface. The reality is that nicotine dependence has not been reduced at the same pace. Instead, it has evolved into new forms, expanded into new populations, and embedded itself more deeply into daily behavioral patterns.
The scale of the problem remains substantial and well documented. The U.S. Centers for Disease Control and Prevention states that “Cigarette smoking remains the leading cause of preventable disease and death in the United States.”¹ It further reports that smoking “kills more than 480,000 Americans each year.”² On a global level, the World Health Organization confirms that tobacco use “kills more than 8 million people each year worldwide.”³ These figures illustrate that despite decades of effort, smoking and nicotine related harm continue to impose a significant burden on healthcare systems, economies, and families around the world.
What has changed is the structure of the nicotine market itself. Over the past decade, vaping has emerged as a major category, fundamentally altering how nicotine is consumed. The CDC explains that “Most e-cigarettes contain nicotine,” and emphasizes that “Nicotine is highly addictive.”⁴ While these products have often been positioned as alternatives to combustible cigarettes, they have in many cases extended the lifecycle of nicotine dependency rather than ending it. In parallel, entirely new demographic segments have entered the market. The CDC reports that “E-cigarettes are the most commonly used tobacco product among U.S. youth,”⁵ and global estimates indicate that “At least 15 million children aged 13 to 15 are estimated to use e-cigarettes.”⁶
Taken together, these trends point to a critical conclusion. The issue is no longer confined to smoking alone. It is a broader, system level challenge centered on nicotine dependence across multiple delivery formats, behavioral triggers, and user segments. This distinction matters because the solutions historically developed for smoking cessation were designed for a different version of the problem. Nicotine replacement therapies such as gum, patches, and lozenges were introduced decades ago and have remained largely unchanged. They were built on the premise of substituting nicotine in a controlled manner, not eliminating it entirely, and they were not designed for a world that includes vaping, dual use, and continuous nicotine exposure throughout the day.
As a result, a gap has emerged between how the problem exists today and how it is being addressed.
At the same time, regulatory and public health priorities are shifting to reflect this new reality. Governments and healthcare systems are increasingly focused not just on reducing cigarette use, but on reducing nicotine dependence in all forms. This broader objective is beginning to influence policy, funding, and the types of solutions that are gaining attention within the healthcare and investment communities. Historically, when regulatory direction, consumer intent, and technological capability begin to align, new categories tend to form. That process is now underway in the nicotine sector.
For investors, this represents a meaningful inflection point. The global smoking cessation market is already measured in billions of dollars, supported by healthcare systems, insurers, and public health initiatives. With more than 1 billion smokers worldwide and continued growth in alternative nicotine use, even modest improvements in cessation outcomes could translate into significant economic and health impacts. However, the next phase of growth in this category is unlikely to come from incremental improvements to legacy nicotine replacement products. It is more likely to come from approaches that are aligned with the current structure of the problem, addressing both the behavioral patterns and the dependency itself without reinforcing the underlying cycle.
This is the context in which Redwood Scientific Technologies is positioned.
Through its TBX FREE and TBX VAPE FREE platforms, Redwood is developing nicotine free oral thin film technologies designed to align with these broader market trends. Rather than relying on nicotine substitution, the company’s approach is focused on eliminating nicotine input while addressing the behavioral aspects associated with smoking and vaping routines. The delivery format itself, oral thin film, reflects a shift toward convenience, discretion, and ease of use, characteristics that are increasingly important in products designed to integrate into real world behavior.
This positioning is not framed as a claim of clinical outcome. It is a reflection of alignment. Alignment with where regulators are directing attention, where consumers are increasingly focused, and where healthcare systems are seeking more effective tools to address long term dependency. In a market defined by transition, that alignment can be a critical factor.
The broader trend is clear. The conversation is moving beyond cigarettes and toward nicotine itself. The market is shifting from substitution to elimination. And the companies that are structured around that shift, rather than anchored to legacy models, may be best positioned to participate in what comes next.
Because the underlying reality has not changed.
The problem did not go away.
It evolved.
Sources and References
- U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html - U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html - World Health Organization
https://www.who.int/news-room/fact-sheets/detail/tobacco - U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/e-cigarettes/health-effects.html - U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/e-cigarettes/youth.html - Reuters citing World Health Organization data
https://www.reuters.com/business/healthcare-pharmaceuticals/who-estimates-least-15-million-teenagers-use-e-cigarettes-worldwide-2025-10-06/
About Redwood Scientific Technologies, Inc.
Redwood Scientific Technologies, Inc. is focused on developing innovative nicotine free technologies designed to help smokers transition away from combustible cigarettes and nicotine based products. The company’s TBX FREE and TBX VAPE FREE platforms are designed to address the behavioral and sensory aspects of smoking cessation while eliminating nicotine.
Redwood has previously achieved large scale commercial distribution of its oral thin film technologies and continues to advance new solutions designed for the global smoking cessation market. With more than 1 billion smokers worldwide and increasing regulatory pressure on both cigarettes and vaping products, demand for effective nicotine free alternatives continues to grow.
Additional information about Redwood Scientific Technologies can be found at
https://redwoodsci.com
Additional Company Disclosure
Redwood Scientific Technologies, Inc. is currently advancing the development of its nicotine free cessation technologies, including TBX FREE and TBX VAPE FREE. The company is in the process of completing required clinical validation through controlled research protocols.
Redwood’s products are not currently being marketed or sold. The company intends to complete a double blind placebo controlled efficacy study covering both product platforms prior to any commercial launch. These studies are designed to evaluate the effectiveness of the products in supporting smoking and vaping cessation and to provide data suitable for scientific publication.
Until those studies are completed and the company finalizes its clinical and regulatory strategy, Redwood Scientific Technologies does not offer these products for sale.
In addition, Redwood’s commercial strategy is structured as a business to business distribution model. The company does not sell products directly to end users or directly to consumers. Instead, Redwood intends to work through licensed distributors, healthcare partners, and institutional channels for future product distribution.
Forward Looking Statement Notice
Certain statements contained in this article constitute forward looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward looking statements include, but are not limited to, statements regarding clinical studies, product development, regulatory strategy, commercialization plans, and market opportunities.
Readers and investors should not place undue reliance on forward looking statements, which speak only as of the date of publication.
This article is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities.